Al Sandrock left Biogen under a cloud last year, his 23 years in R&D leadership at the company ending abruptly amid growing controversy around its Alzheimer’s therapy Aduhelm (aducanumab).
It was a disappointing end to his time at the company, where he had developed some of the most important neuroscience drugs of recent decades, such as the multiple sclerosis treatment Tecfidera (dimethyl fumarate) the rare disease antisense therapy